Video Experimental Relacionado
Updated: Jul 29, 2026
06:39
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
El polimorfismo del promotor 5A/6A de la estromelisina está asociado con el infarto agudo de miocardio
M Terashima1, H Akita, K Kanazawa
1First Department of Internal Medicine, Kobe University School of Medicine, Kobe, and Himeji Cardiovascular Center, Hyogo, Japan.
Circulation
|June 3, 1999
Resumen
Una variante genética común, el polimorfismo 5A/6A en el promotor del gen de la estromelisina, es un factor de riesgo significativo para el infarto agudo de miocardio (AMI). Este hallazgo pone de relieve una nueva vía que contribuye a los ataques cardíacos.
Área de la Ciencia:
- Genética cardiovascular Genética cardiovascular Genética cardiovascular Genética cardiovascular Genética cardiovascular
- Biología Molecular Biología Molecular
- La patogénesis de la aterosclerosis
Sus antecedentes:
- La ruptura de la placa es un evento crítico que conduce al infarto agudo del miocardio (AMI).
- Las metaloproteinasas matriciales (MMP), incluida la estromelisina, están implicadas en el debilitamiento de las tapas ateroscleróticas de la placa.
- Un polimorfismo 5A/6A común en el promotor del gen de la estromelisina puede influir en la transcripción génica.
Objetivo del estudio:
- Investigar la asociación entre el polimorfismo del gen 5A/6A de la estromelisina y el riesgo de IAM.
- Determinar si esta variante genética es un factor de riesgo independiente para la IAM.
Principales métodos:
- Se realizó un estudio de caso-control con 330 pacientes con IAM y 330 sujetos de control.
- Se realizó genotipización para el polimorfismo 5A/6A en el promotor del gen de la estromelisina.
- El análisis estadístico, incluida la regresión logística, se utilizó para evaluar la asociación.
Principales resultados:
- El genotipo 5A / 6A + 5A / 5A fue significativamente más frecuente en pacientes con IAM (48,8%) en comparación con los controles (32,7%).
- La relación de probabilidades para la IAM asociada con el genotipo 5A / 6A + 5A / 5A fue de 2,25.
- La asociación se mantuvo estadísticamente significativa e independiente de otros factores de riesgo cardiovascular.
Conclusiones:
- El polimorfismo 5A/6A en el promotor del gen de la estromelisina representa un nuevo factor de riesgo patogenético para la IAM.
- Esta variante genética puede desempeñar un papel en el desarrollo y la progresión del infarto agudo de miocardio.
Videos de Conceptos Relacionados
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...